These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 28082069)
1. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment. Hroch L; Guest P; Benek O; Soukup O; Janockova J; Dolezal R; Kuca K; Aitken L; Smith TK; Gunn-Moore F; Zala D; Ramsay RR; Musilek K Bioorg Med Chem; 2017 Feb; 25(3):1143-1152. PubMed ID: 28082069 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment. Hroch L; Benek O; Guest P; Aitken L; Soukup O; Janockova J; Musil K; Dohnal V; Dolezal R; Kuca K; Smith TK; Gunn-Moore F; Musilek K Bioorg Med Chem Lett; 2016 Aug; 26(15):3675-8. PubMed ID: 27287370 [TBL] [Abstract][Full Text] [Related]
3. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Xie Y; Deng S; Chen Z; Yan S; Landry DW Bioorg Med Chem Lett; 2006 Sep; 16(17):4657-60. PubMed ID: 16781151 [TBL] [Abstract][Full Text] [Related]
4. Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer's Disease Treatment. Schmidt M; Benek O; Vinklarova L; Hrabinova M; Zemanova L; Chribek M; Kralova V; Hroch L; Dolezal R; Lycka A; Prchal L; Jun D; Aitken L; Gunn-Moore F; Kuca K; Musilek K Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192199 [TBL] [Abstract][Full Text] [Related]
5. Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer's Disease Treatment. Aitken L; Benek O; McKelvie BE; Hughes RE; Hroch L; Schmidt M; Major LL; Vinklarova L; Kuca K; Smith TK; Musilek K; Gunn-Moore FJ Molecules; 2019 Jul; 24(15):. PubMed ID: 31362457 [No Abstract] [Full Text] [Related]
6. 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. Benek O; Hroch L; Aitken L; Gunn-Moore F; Vinklarova L; Kuca K; Perez DI; Perez C; Martinez A; Fisar Z; Musilek K J Enzyme Inhib Med Chem; 2018 Dec; 33(1):665-670. PubMed ID: 29536773 [TBL] [Abstract][Full Text] [Related]
7. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics. Kissinger CR; Rejto PA; Pelletier LA; Thomson JA; Showalter RE; Abreo MA; Agree CS; Margosiak S; Meng JJ; Aust RM; Vanderpool D; Li B; Tempczyk-Russell A; Villafranca JE J Mol Biol; 2004 Sep; 342(3):943-52. PubMed ID: 15342248 [TBL] [Abstract][Full Text] [Related]
8. Tacrine - Benzothiazoles: Novel class of potential multitarget anti-Alzheimeŕs drugs dealing with cholinergic, amyloid and mitochondrial systems. Nepovimova E; Svobodova L; Dolezal R; Hepnarova V; Junova L; Jun D; Korabecny J; Kucera T; Gazova Z; Motykova K; Kubackova J; Bednarikova Z; Janockova J; Jesus C; Cortes L; Pina J; Rostohar D; Serpa C; Soukup O; Aitken L; Hughes RE; Musilek K; Muckova L; Jost P; Chvojkova M; Vales K; Valis M; Chrienova Z; Chalupova K; Kuca K Bioorg Chem; 2021 Feb; 107():104596. PubMed ID: 33421953 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17β-HSD10 Inhibitors as Therapeutics in Alzheimer's Disease. Aitken L; Baillie G; Pannifer A; Morrison A; Jones PS; Smith TK; McElroy SP; Gunn-Moore FJ SLAS Discov; 2017 Jul; 22(6):676-685. PubMed ID: 28314118 [TBL] [Abstract][Full Text] [Related]
10. Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease. Morsy A; Trippier PC J Med Chem; 2019 May; 62(9):4252-4264. PubMed ID: 30444369 [TBL] [Abstract][Full Text] [Related]
11. 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation. Benek O; Hroch L; Aitken L; Dolezal R; Guest P; Benkova M; Soukup O; Musil K; Kuca K; Smith TK; Gunn-Moore F; Musilek K Med Chem; 2017 Jan; ():. PubMed ID: 28067167 [TBL] [Abstract][Full Text] [Related]
12. Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction. Valaasani KR; Sun Q; Hu G; Li J; Du F; Guo Y; Carlson EA; Gan X; Yan SS Curr Alzheimer Res; 2014 Feb; 11(2):128-36. PubMed ID: 24479630 [TBL] [Abstract][Full Text] [Related]
13. 3-Hydroxyacyl-CoA and Alcohol Dehydrogenase Activities of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in Neurodegeneration Study. He XY; Dobkin C; Brown WT; Yang SY J Alzheimers Dis; 2022; 88(4):1487-1497. PubMed ID: 35786658 [TBL] [Abstract][Full Text] [Related]
14. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Youdim MB; Fridkin M; Zheng H Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213 [TBL] [Abstract][Full Text] [Related]
15. ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease. Marques AT; Fernandes PA; Ramos MJ Mini Rev Med Chem; 2009 Jul; 9(8):1002-8. PubMed ID: 19601895 [TBL] [Abstract][Full Text] [Related]
16. Infantile Neurodegeneration Results from Mutants of 17β-Hydroxysteroid Dehydrogenase Type 10 Rather Than Aβ-Binding Alcohol Dehydrogenase. He XY; Dobkin C; Brown WT; Yang SY Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239833 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Xu YX; Wang H; Li XK; Dong SN; Liu WW; Gong Q; Wang TD; Tang Y; Zhu J; Li J; Zhang HY; Mao F Eur J Med Chem; 2018 Jan; 143():33-47. PubMed ID: 29172081 [TBL] [Abstract][Full Text] [Related]
18. Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Aβ for treatment of Alzheimer's disease. Valasani KR; Hu G; Chaney MO; Yan SS Chem Biol Drug Des; 2013 Feb; 81(2):238-49. PubMed ID: 23039767 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease. Yang HL; Cai P; Liu QH; Yang XL; Li F; Wang J; Wu JJ; Wang XB; Kong LY Eur J Med Chem; 2017 Sep; 138():715-728. PubMed ID: 28728104 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]